Syndax Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 2, 2026, reporting total revenues of $83.3 million for the third quarter and disclosing a new convertible note liability on its balance sheet.

Key Highlights

  • Total Q3 2026 revenues: $83,298 thousand, up from $45,871 thousand in Q3 2025, according to the filing.
  • Product revenue, net: $60,743 thousand for the three months ended September 30, 2026, compared to $32,007 thousand in the same period of 2025.
  • Collaboration revenue, net: $22,555 thousand for Q3 2026, versus $13,864 thousand for Q3 2025.
  • Nine-month total revenues: $220,950 thousand for the nine months ended September 30, 2026, compared to $103,624 thousand for the same period in 2025.
  • Convertible note liability: $244,187 thousand recorded as a long-term liability as of September 30, 2026, compared to zero at December 31, 2025.
  • Accumulated deficit: $(1,648,049) thousand as of September 30, 2026, versus $(1,506,580) thousand at December 31, 2025.
  • Shares outstanding: 90,028,256 shares of common stock as of October 29, 2026, per the filing's cover page.

Syndax Revenue and Balance Sheet Position for the Quarter Ended September 30, 2026

According to the filing, Syndax Pharmaceuticals (NASDAQ:SNDX) reported total revenues of $83,298 thousand for the three months ended September 30, 2026, nearly doubling the $45,871 thousand reported in the comparable prior-year quarter. The increase was driven by both product revenue and collaboration revenue. Product revenue, net, reached $60,743 thousand in Q3 2026, up from $32,007 thousand in Q3 2025. Collaboration revenue, net, was $22,555 thousand for the quarter, compared to $13,864 thousand a year earlier. The filing identifies REVUFORJ (revumenib) and NIKTIMVO (axatilimab-csfr) as the company's marketed products.

For the nine months ended September 30, 2026, the registrant reported total revenues of $220,950 thousand, versus $103,624 thousand for the nine months ended September 30, 2025. On the balance sheet, total assets stood at $692,671 thousand as of September 30, 2026, compared to $529,706 thousand at December 31, 2025. A notable change was the appearance of a convertible note liability of $244,187 thousand in long-term liabilities, which carried a balance of zero at year-end 2025. The royalty interest financing liability was $344,095 thousand at September 30, 2026, versus $343,909 thousand at December 31, 2025.

The company reported total stockholders' deficit of $(17,180) thousand at September 30, 2026, a shift from stockholders' equity of $64,630 thousand at December 31, 2025. The accumulated deficit widened to $(1,648,049) thousand from $(1,506,580) thousand over the same interval. Common shares issued and outstanding increased to 89,989,347 at September 30, 2026, from 87,405,979 at December 31, 2025. The filing notes that forward-looking statements contained therein "are subject to known and unknown risks, uncertainties and other factors" and are the company's own characterizations, not guarantees of future performance.

What Was Disclosed

Syndax Pharmaceuticals filed its quarterly report covering the period ended September 30, 2026, disclosing total revenues of $83,298 thousand for Q3 2026, a new $244,187 thousand convertible note liability, and an accumulated deficit of $(1,648,049) thousand.